These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9519176)

  • 1. The absence of 'cross-tolerance' when switching from oral morphine to transdermal fentanyl.
    Johnson S; Faull C
    Palliat Med; 1997 Nov; 11(6):494-5. PubMed ID: 9519176
    [No Abstract]   [Full Text] [Related]  

  • 2. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy switching in patients receiving long-acting opioids.
    Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
    Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
    Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
    Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The opioid combination of transdermal fentanyl and sustained release morphine for refractory cancer pain--a case report].
    Shinjo T; Okada M
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1997-2000. PubMed ID: 16282744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
    van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW
    Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain.
    Tani M; Fuku A; Terashita S; Kashiwagi H; Yukawa H; Yamaue H
    Hepatogastroenterology; 2008; 55(86-87):1545-8. PubMed ID: 19102339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial.
    Morita T; Takigawa C; Onishi H; Tajima T; Tani K; Matsubara T; Miyoshi I; Ikenaga M; Akechi T; Uchitomi Y;
    J Pain Symptom Manage; 2005 Jul; 30(1):96-103. PubMed ID: 16043013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
    Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Transdermal opioid administration: the pain plaster].
    Vecht CJ; Sillevis Smitt PA
    Ned Tijdschr Geneeskd; 1997 Apr; 141(17):821-3. PubMed ID: 9221362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Direct conversion from low-dose morphine to transdermal fentanyl: efficacy for cancer pain and quality of life].
    Yamazaki M; Aoki T; Tachibana M; Akashi T
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):217-21. PubMed ID: 16484859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transdermal route as an alternative to oral administration of opioids in cancer pain].
    Burza M; Ginobbi P; Fusco G; Laurenzi L; Tirelli W; Arcuri E
    Clin Ter; 1998; 149(4):277-80. PubMed ID: 9866889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
    Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
    Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
    Sittl R; Likar R; Nautrup BP
    Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of transdermal morphine and fentanyl pluronic lecithin organogel administration in dogs.
    Krotscheck U; Boothe DM; Boothe HW
    Vet Ther; 2004; 5(3):202-11. PubMed ID: 15578452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Usefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparations].
    Akiyama Y; Iseki M; Izawa R; Ishii K; Miyazaki T; Yamaguchi S; Tani Y
    Masui; 2007 Mar; 56(3):317-23. PubMed ID: 17366919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inefficacy of high-dose transdermal fentanyl in a patient with neuropathic pain, a case report.
    Bleeker CP; Bremer RC; Dongelmans DA; van Dongen RT; Crul BJ
    Eur J Pain; 2001; 5(3):325-9; discussion 329-31. PubMed ID: 11558988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effective analysis of rotation from sustained-release morphine tablet to transdermal fentanyl of matrix type or sustained-release oxycodone tablet].
    Ise Y; Wako T; Miura Y; Katayama S; Shimizu H
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2599-603. PubMed ID: 20009462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Home palliative care--2 case reports: a long-term cancer pain management with transdermal fentanyl].
    Fujimoto M; Sakuyama T; Mizutani Y; Kuroda T; Yanaga K
    Gan To Kagaku Ryoho; 2004 Dec; 31 Suppl 2():190-3. PubMed ID: 15645768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pitfall to avoid when starting a patient on transdermal fentanyl.
    Low JA; Chye R
    Aust Fam Physician; 2000 Dec; 29(12):1173-5. PubMed ID: 11140227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.